NIH awarded $200.8M contract to Novartis for vaccine development, spanning 5 years

Contract Overview

Contract Amount: $20,080,810 ($20.1M)

Contractor: Novartis Vaccines and Diagnostics, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2000-06-15

End Date: 2005-06-04

Contract Duration: 1,815 days

Daily Burn Rate: $11.1K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 11

Pricing Type: COST NO FEE

Sector: Healthcare

Place of Performance

Location: EMERYVILLE, ALAMEDA County, CALIFORNIA, 94608

State: California Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $20.1 million to NOVARTIS VACCINES AND DIAGNOSTICS, INC. for work described as: Key points: 1. Contract value appears reasonable given the 5-year duration and the critical nature of vaccine research. 2. Full and open competition suggests a robust bidding process, likely leading to competitive pricing. 3. The contract's cost-plus-fee structure may incentivize contractor efficiency and cost control. 4. Performance period of 5 years allows for sustained research and development in a complex field. 5. This contract aligns with NIH's mission to advance biomedical research and public health. 6. The absence of small business set-asides warrants further examination of subcontracting opportunities.

Value Assessment

Rating: good

The contract's total value of $200.8 million over five years averages to approximately $40 million annually. This figure is within a reasonable range for large-scale vaccine research and development projects, especially considering the potential for significant scientific breakthroughs. Benchmarking against similar contracts for advanced biomedical research would provide a more precise value assessment, but the initial indication suggests fair pricing for the scope of work.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that all responsible sources were permitted to submit bids. With 11 bids received, the level of competition was substantial. This broad participation suggests that the government likely secured competitive pricing and a wide range of technical approaches. The presence of multiple bidders generally leads to better price discovery and a higher likelihood of selecting the most capable contractor.

Taxpayer Impact: A competitive bidding process for this significant contract ensures that taxpayer dollars are used efficiently, driving down costs and maximizing the value received for public health initiatives.

Public Impact

The primary beneficiaries are the public, through the potential development of new vaccines. Services delivered include research, development, and potentially manufacturing support for vaccines. The geographic impact is national, with potential global health implications. Workforce implications include employment for scientists, researchers, and support staff at NIH and Novartis.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns in long-term R&D projects.
Dependence on a single large contractor for critical vaccine development.
Limited visibility into specific research milestones and progress without detailed reporting.

Positive Signals

Full and open competition suggests a strong market assessment and competitive pricing.
The contract's duration allows for sustained focus on complex research objectives.
Novartis's established expertise in vaccines is a positive signal for project success.

Sector Analysis

This contract falls within the Biotechnology and Pharmaceutical sector, a critical area for public health and national security. The market for vaccine development is highly specialized, characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Spending in this sector by agencies like NIH is essential for addressing emerging health threats and maintaining a robust pipeline of medical countermeasures. Comparable spending benchmarks would involve other large-scale R&D grants and contracts awarded for novel therapeutic and vaccine development.

Small Business Impact

The contract was not set aside for small businesses, and there is no indication of specific subcontracting requirements for small businesses in the provided data. This suggests that the primary focus was on securing the most capable large-scale contractor for this complex research. Further investigation into subcontracting plans would be necessary to determine the extent of small business participation and its potential impact on the small business ecosystem.

Oversight & Accountability

Oversight for this contract would primarily reside with the National Institutes of Health (NIH), a component of the Department of Health and Human Services. Mechanisms likely include regular progress reports, milestone reviews, and financial audits. The Inspector General of HHS would have jurisdiction for investigating any potential fraud, waste, or abuse related to this contract, ensuring accountability and transparency in the use of federal funds.

Related Government Programs

National Vaccine Program Office
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC) vaccine initiatives
National Institute of Allergy and Infectious Diseases (NIAID) research grants

Risk Flags

Long-term R&D projects carry inherent scientific and financial risks.
Potential for scope creep or unforeseen technical challenges impacting cost and schedule.
Dependence on contractor's continued innovation and adherence to quality standards.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $20.1 million to NOVARTIS VACCINES AND DIAGNOSTICS, INC.. See the official description on USAspending.

Who is the contractor on this award?

The obligated recipient is NOVARTIS VACCINES AND DIAGNOSTICS, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $20.1 million.

What is the period of performance?

Start: 2000-06-15. End: 2005-06-04.

What is Novartis's track record with federal vaccine development contracts?

Novartis Vaccines and Diagnostics, Inc. has a significant history of engaging with federal agencies on vaccine research and development. While specific details of past federal contracts are not provided here, the company is a major global player in the pharmaceutical industry with a dedicated vaccine division. Their experience likely includes navigating complex regulatory pathways, managing large-scale R&D projects, and collaborating with government entities on public health initiatives. A deeper dive into their contract history with NIH, BARDA, and DoD would reveal specific successes, challenges, and performance metrics on similar projects. This context is crucial for assessing their capability to deliver on the current $200.8 million contract.

How does the $200.8 million contract value compare to similar NIH vaccine R&D awards?

The $200.8 million awarded to Novartis over five years, averaging approximately $40 million annually, is substantial but falls within the expected range for major vaccine development initiatives funded by the National Institutes of Health. NIH frequently awards large contracts and grants for cutting-edge biomedical research, including vaccine development for infectious diseases and other health threats. Benchmarking this specific award against other NIH contracts for similar research scope, duration, and therapeutic areas would provide a clearer picture of its relative value. Factors such as the novelty of the vaccine target, the complexity of the research, and the required scale of development would influence the appropriate contract value. Without direct comparative data, the award appears commensurate with the scale of advanced R&D.

What are the primary risks associated with this long-term vaccine development contract?

The primary risks associated with this long-term vaccine development contract are inherent to the nature of research and development, particularly in the pharmaceutical sector. Scientific risk is paramount; the research may not yield a viable vaccine candidate, or efficacy and safety hurdles may prove insurmountable during clinical trials. Financial risk exists, as R&D projects can exceed initial cost estimates due to unforeseen technical challenges or extended timelines. There's also a risk of market or public health shifts; the targeted disease may evolve, or a competing vaccine may emerge, diminishing the project's impact. Furthermore, reliance on a single contractor, even a reputable one like Novartis, introduces program risk if the contractor faces internal issues, such as financial instability or shifts in strategic priorities. Regulatory risk is also a factor, as the path to FDA approval is complex and uncertain.

How effective is the 'full and open competition' strategy for securing innovative vaccine solutions?

The 'full and open competition' strategy is generally effective for securing a broad range of potential solutions and ensuring competitive pricing in complex procurements like vaccine development. By allowing all responsible sources to bid, NIH maximizes the pool of innovative ideas and technological approaches. This approach encourages companies to present their best capabilities and pricing, fostering a dynamic market. The presence of 11 bidders in this case suggests significant industry interest and a healthy competitive environment. While competition drives efficiency, the ultimate effectiveness also depends on the clarity of the solicitation's technical requirements and evaluation criteria. Ensuring that the evaluation process properly assesses scientific merit and innovation, not just cost, is crucial for selecting the most promising vaccine development proposals.

What is the historical spending pattern for vaccine R&D at NIH over the last decade?

Historical spending patterns for vaccine R&D at the National Institutes of Health (NIH) over the last decade show a consistent and significant investment, often fluctuating based on emerging public health threats and national priorities. NIH, through its various institutes like NIAID, allocates billions annually to a wide spectrum of biomedical research, with a substantial portion dedicated to vaccine development. Spending typically increases during outbreaks (e.g., H1N1, Ebola, Zika, and more recently COVID-19) as agencies rapidly fund research and development efforts. While specific annual figures for vaccine R&D alone are complex to isolate due to the integrated nature of biomedical research funding, overall NIH extramural research funding has generally trended upwards. The $200.8 million awarded to Novartis represents a significant, but not unprecedented, investment for a multi-year, large-scale vaccine project within this broader funding landscape.

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Offers Received: 11

Pricing Type: COST NO FEE (S)

Contractor Details

Parent Company: Novartis AG

Address: 4560 HORTON ST, EMERYVILLE, CA, 94608

Business Categories: Category Business, Not Designated a Small Business

Financial Breakdown

Contract Ceiling: $2,947,422

Exercised Options: $2,947,422

Current Obligation: $20,080,810

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Timeline